My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

56.56 -2.18 (-3.71%)
Streaming Delayed Price Updated: 11:06 AM EDT, Sep 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 7,764,751
Open 57.14
Bid (Size) 56.55 (3)
Ask (Size) 56.56 (1)
Prev. Close 58.74
Today's Range 56.43 - 57.35
52wk Range 45.05 - 127.61
Shares Outstanding N/A
Dividend Yield 3.89%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Faruqi & Faruqi Reminds Novo Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of September 30, 2025 - NVO
From Faruqi & Faruqi LLP
Via GlobeNewswire
Does This Acquisition Make Pfizer Stock a Great Buy?
There's an opportunity to get in on the weight-loss drug craze at a reasonable price. 
Via The Motley Fool
Topics Death Intellectual Property

Performance

YTD
-35.4%
-35.4%
1 Month
+0.4%
+0.4%
3 Month
-16.0%
-16.0%
6 Month
-21.1%
-21.1%
1 Year
-54.9%
-54.9%

More News

Read More
DEADLINE NEXT WEEK: Berger Montague Advises Novo Nordisk A/S (NYSE: NVO) Investors to Contact the Firm Before September 30, 2025
From Berger Montague
Via GlobeNewswire
Chinese Biotech Takes Aim At Eli Lilly, Novo Nordisk With New GLP-1 Weight-Loss Drugs As Patent Clocks Tick
Via Stocktwits
Topics Intellectual Property
NOVO NORDISK A/S (NYSE: NVO) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Novo Nordisk A/S Investors of Upcoming Deadline
From Bernstein Liebhard LLP
Via GlobeNewswire
1 Reason Novo Nordisk (NVO) Is 1 of the Best Healthcare Stocks You Can Buy Today
Via The Motley Fool
Topics Economy
3 Reasons to Buy Novo Nordisk Stock Right Now
Via The Motley Fool
NOVO DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors a Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S and Encourages Investors to Contact the Firm Before September 30th
From Bragar Eagel & Squire
Via GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming Deadlines - NVO
From Pomerantz LLP
Via GlobeNewswire
Direxion's Ultra-Leveraged CURE ETF Offers An Opportunity To Play The Potential Valuation Reset
Via Benzinga
Topics ETFs
NVO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important September 30 Deadline in Securities Class Action - NVO
From The Rosen Law Firm PA
Via GlobeNewswire
Scholar Rock, A Top 10% Stock, Dives After Catalent Issues Hamper SMA Drug
Via Investor's Business Daily
Top 5 Stocks to Watch in Q4 2025: Navigating a Shifting Economic Landscape
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Big Pharma's Epicenter Shift: Eli Lilly and the Reshaping of the Weight-Loss Drug Market
Via MarketMinute
Topics Economy Intellectual Property
Roche Targets Top Spot In Weight Loss Drug Market
Via Benzinga
Growth Titans: Eli Lilly's Weight-Loss Surge vs. Johnson & Johnson's Diversified Might
Via MarketMinute
Topics Artificial Intelligence Economy Intellectual Property
Eli Lilly's Ascent: A New Era in Obesity Treatment Driven by Zepbound and Orforglipron
Via MarketMinute
Topics Economy
Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO
Via NewMediaWire
Topics Fraud Lawsuit
Levi & Korsinsky Reminds Novo Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 30, 2025 - NVO
Via TheNewswire.com
Topics Fraud Lawsuit
3 Dirt-Cheap Stocks to Buy Right Now
Via The Motley Fool
Topics Intellectual Property
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Novo Nordisk A/S (NYSE: NVO)
From Bernstein Liebhard LLP
Via GlobeNewswire
Pfizer Reportedly Nears Metsera Acquisition Deal: PFE Stock Climbs In Monday Pre-Market
Via Benzinga
NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) Emerges as a Top Affordable Growth Stock
Via Chartmill
Benzinga Bulls And Bears: Intel, FedEx, Cracker Barrel — And Markets Close At Record Highs
Via Benzinga
Is Novo Nordisk Stock a Buy Now?
Via The Motley Fool
Topics Economy

Frequently Asked Questions

Is Novo Nordisk A/S Common Stock publicly traded?
Yes, Novo Nordisk A/S Common Stock is publicly traded.
What exchange does Novo Nordisk A/S Common Stock trade on?
Novo Nordisk A/S Common Stock trades on the New York Stock Exchange
What is the ticker symbol for Novo Nordisk A/S Common Stock?
The ticker symbol for Novo Nordisk A/S Common Stock is NVO on the New York Stock Exchange
What is the current price of Novo Nordisk A/S Common Stock?
The current price of Novo Nordisk A/S Common Stock is 56.56
When was Novo Nordisk A/S Common Stock last traded?
The last trade of Novo Nordisk A/S Common Stock was at 09/25/25 11:06 AM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.